| pubmed-article:17634541 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17634541 | lifeskim:mentions | umls-concept:C1140680 | lld:lifeskim |
| pubmed-article:17634541 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:17634541 | lifeskim:mentions | umls-concept:C0021747 | lld:lifeskim |
| pubmed-article:17634541 | lifeskim:mentions | umls-concept:C0085862 | lld:lifeskim |
| pubmed-article:17634541 | lifeskim:mentions | umls-concept:C1299583 | lld:lifeskim |
| pubmed-article:17634541 | lifeskim:mentions | umls-concept:C1415900 | lld:lifeskim |
| pubmed-article:17634541 | lifeskim:mentions | umls-concept:C1514474 | lld:lifeskim |
| pubmed-article:17634541 | lifeskim:mentions | umls-concept:C1823153 | lld:lifeskim |
| pubmed-article:17634541 | lifeskim:mentions | umls-concept:C2349976 | lld:lifeskim |
| pubmed-article:17634541 | lifeskim:mentions | umls-concept:C1552644 | lld:lifeskim |
| pubmed-article:17634541 | lifeskim:mentions | umls-concept:C1608386 | lld:lifeskim |
| pubmed-article:17634541 | lifeskim:mentions | umls-concept:C1549571 | lld:lifeskim |
| pubmed-article:17634541 | lifeskim:mentions | umls-concept:C1517945 | lld:lifeskim |
| pubmed-article:17634541 | pubmed:issue | 14 | lld:pubmed |
| pubmed-article:17634541 | pubmed:dateCreated | 2007-7-19 | lld:pubmed |
| pubmed-article:17634541 | pubmed:abstractText | There is evidence that IFN gamma plays an important role in ovarian cancer development. IFN gamma produces numerous antitumor effects and it may be evasion of these effects which allows tumor progression. We postulate that genetic instability in tumor cells may lead to modulation of expression of the IFN gamma receptor, thus leading to altered tumor biology and patient prognosis. This hypothesis would support the theory of immunoediting in ovarian cancer. | lld:pubmed |
| pubmed-article:17634541 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17634541 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17634541 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17634541 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17634541 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17634541 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17634541 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17634541 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:17634541 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:17634541 | pubmed:author | pubmed-author:SpendloveIanI | lld:pubmed |
| pubmed-article:17634541 | pubmed:author | pubmed-author:DurrantLindy... | lld:pubmed |
| pubmed-article:17634541 | pubmed:author | pubmed-author:RollandPhilP | lld:pubmed |
| pubmed-article:17634541 | pubmed:author | pubmed-author:DuncanTimothy... | lld:pubmed |
| pubmed-article:17634541 | pubmed:author | pubmed-author:DeenSuhaS | lld:pubmed |
| pubmed-article:17634541 | pubmed:author | pubmed-author:ScottIan VIV | lld:pubmed |
| pubmed-article:17634541 | pubmed:author | pubmed-author:LiuDavid T... | lld:pubmed |
| pubmed-article:17634541 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17634541 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:17634541 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:17634541 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17634541 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17634541 | pubmed:pagination | 4139-45 | lld:pubmed |
| pubmed-article:17634541 | pubmed:meshHeading | pubmed-meshheading:17634541... | lld:pubmed |
| pubmed-article:17634541 | pubmed:meshHeading | pubmed-meshheading:17634541... | lld:pubmed |
| pubmed-article:17634541 | pubmed:meshHeading | pubmed-meshheading:17634541... | lld:pubmed |
| pubmed-article:17634541 | pubmed:meshHeading | pubmed-meshheading:17634541... | lld:pubmed |
| pubmed-article:17634541 | pubmed:meshHeading | pubmed-meshheading:17634541... | lld:pubmed |
| pubmed-article:17634541 | pubmed:meshHeading | pubmed-meshheading:17634541... | lld:pubmed |
| pubmed-article:17634541 | pubmed:meshHeading | pubmed-meshheading:17634541... | lld:pubmed |
| pubmed-article:17634541 | pubmed:meshHeading | pubmed-meshheading:17634541... | lld:pubmed |
| pubmed-article:17634541 | pubmed:meshHeading | pubmed-meshheading:17634541... | lld:pubmed |
| pubmed-article:17634541 | pubmed:meshHeading | pubmed-meshheading:17634541... | lld:pubmed |
| pubmed-article:17634541 | pubmed:meshHeading | pubmed-meshheading:17634541... | lld:pubmed |
| pubmed-article:17634541 | pubmed:meshHeading | pubmed-meshheading:17634541... | lld:pubmed |
| pubmed-article:17634541 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17634541 | pubmed:articleTitle | Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer. | lld:pubmed |
| pubmed-article:17634541 | pubmed:affiliation | Academic and Clinical Department of Oncology, University of Nottingham, Nottingham, UK. | lld:pubmed |
| pubmed-article:17634541 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17634541 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17634541 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17634541 | lld:pubmed |
